Exploring the antiplatelet activity of serotonin 5-HT2A receptor antagonists bearing 6-fluorobenzo[d]isoxazol-3-yl)propyl) motif– as potential therapeutic agents in the prevention of cardiovascular diseases

The article analyzes properties of potassium and magnesium, which may exert vasodilatory, anti-inflammatory, anti-ischemic, antiaggregant, and antiarrhythmic effects. These are extremely important microelements and potentially beneficial therapeutic agents for treatment of cardiovascular diseases.

Download Full-text

Extracellular Vesicles in Cardiovascular Diseases: Alternative Biomarker Sources, Therapeutic Agents, and Drug Delivery Carriers

International Journal of Molecular Sciences ◽

10.3390/ijms20133272 ◽

2019 ◽

Vol 20 (13) ◽

pp. 3272 ◽

Cited By ~ 16

Author(s):

Suet Yen Chong ◽

Choon Keong Lee ◽

Chenyuan Huang ◽

Yi Hsuan Ou ◽

Christopher J. Charles ◽

...

Keyword(s):

Drug Delivery ◽

Cardiovascular Diseases ◽

Extracellular Vesicles ◽

Biological Fluids ◽

Therapeutic Agents ◽

Bioactive Molecules ◽

Intrinsic Activity ◽

Diagnostic Tools ◽

Alternative Source ◽

Technological Advantage

Cardiovascular diseases (CVD) represent the leading cause of morbidity and mortality globally. The emerging role of extracellular vesicles (EVs) in intercellular communication has stimulated renewed interest in exploring the potential application of EVs as tools for diagnosis, prognosis, and therapy in CVD. The ubiquitous nature of EVs in biological fluids presents a technological advantage compared to current diagnostic tools by virtue of their notable stability. EV contents, such as proteins and microRNAs, represent specific signatures of cellular activation or injury. This feature positions EVs as an alternative source of biomarkers. Furthermore, their intrinsic activity and immunomodulatory properties offer EVs unique opportunities to act as therapeutic agents per se or to serve as drug delivery carriers by acting as miniaturized vehicles incorporating bioactive molecules. In this article, we aim to review the recent advances and applications of EV-based biomarkers and therapeutics. In addition, the potential of EVs as a drug delivery and theranostic platform for CVD will also be discussed.

Download Full-text

Iron Oxide Nanoparticles as Imaging and Therapeutic Agents for Atherosclerosis

Seminars in Thrombosis and Hemostasis ◽

10.1055/s-0039-3400247 ◽

2020 ◽

Vol 46 (05) ◽

pp. 553-562

Author(s):

Joshua Talev ◽

Jagat Rakesh Kanwar

Keyword(s):

Iron Oxide ◽

Cardiovascular Diseases ◽

Iron Oxide Nanoparticles ◽

Imaging Techniques ◽

Therapeutic Agents ◽

Oxide Nanoparticles ◽

Future Prospects ◽

Wide Range ◽

Theranostic Applications

AbstractAtherosclerosis is the major cause of cardiovascular diseases and is the leading cause of mortality worldwide. Iron oxide nanoparticles have emerged as potential diagnostic and therapeutic agents for a wide range of conditions. To date, the theranostic applications of iron oxide nanoparticles have been studied mainly in cancer, but atherosclerosis has not received the same attention. Therefore, it appears appropriate to review the current and future applications of iron oxide nanoparticles for the diagnosis and therapy of atherosclerosis. This review will first discuss current imaging techniques for the diagnosis of atherosclerosis as well as their limitations. It will then discuss the role of nanotechnology for molecular imaging of atherosclerosis and the benefits of this approach as well as reviewing current developments in the field including single, bi-, and tri-modal imaging. Next, it will discuss the role of nanotechnology for therapies of atherosclerosis with a focus on nanotheranostics, concluding with a look at the challenges faced by nanoparticle-based imaging and therapy of atherosclerosis as well as a look at future prospects.

Download Full-text